Status:
RECRUITING
Study on the Role and Mechanism of Plasma Exosome microRNAs in Cognitive Impairment in First-episode Schizophrenia
Lead Sponsor:
Tianjin Anding Hospital
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Brief Summary
Schizophrenia is a severe mental illness characterised by positive symptoms, negative symptoms, and cognitive symptoms. In recent years, an increasing number of doctors and scholars have focused on co...
Detailed Description
This single-center, prospective cohort study will enroll 200 drug-naive schizophrenia patients and 100 demographically matched healthy volunteers to identify biological signatures of cognitive impairm...
Eligibility Criteria
Inclusion
- Healthy volunteers matched to the patient group on sex, age, and education level;
- No family history of psychiatric disorders among first- or second-degree relatives (two generations);
- Ethnic Han Chinese;
- Able and willing to provide written informed consent.
Exclusion
- Any serious physical illness, including but not limited to uncontrolled hypertension, severe cardiovascular, cerebrovascular, pulmonary, thyroid, or metabolic disease, diabetes, epilepsy, or metabolic syndrome;
- Current or past diagnosis of substance-induced psychotic disorder, delusional disorder, brief psychotic disorder, or mood disorder with psychotic features;
- Pregnancy or breastfeeding;
- Any condition that would interfere with the ability to give informed consent or complete study procedures.
Key Trial Info
Start Date :
November 11 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT07139171
Start Date
November 11 2022
End Date
December 31 2025
Last Update
September 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tianjin Anding Hospital
Tianjin, China